Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Portugal

被引：0

作者：

Silva, C. ^{[1
]}

Alves, C. ^{[1
]}

Negreiro, F. ^{[1
]}

Fonseca, M. A. ^{[2
]}

Aagren, M. ^{[3
]}

机构：

[1] Eurotrials, Lisbon, Portugal

[2] Novo Nordisk Lda, Paco de Arcos, Portugal

[3] Novo Nordisk AS, Virum, Denmark

来源：

VALUE IN HEALTH | 2008年 / 11卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)70719-1

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A227 / A227

页数：1

共 50 条

[1] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
[J]. DIABETOLOGIA, 2007, 50 : S428 - S428
[2] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Australia: A modeling evaluation based on results from a 2-year clinical trial
Fulcher, Gregory R.
Aagren, Mark
[J]. DIABETES, 2008, 57 : A338 - A339
[3] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
[J]. DIABETOLOGIA, 2005, 48 : A334 - A334
[4] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
[J]. DIABETES, 2005, 54 : A609 - A609
[5] Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Scheilbeler, H.
Aagren, M.
Nielsen, S.
Goodall, G.
Kotchie, R.
Valentine, W. J.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
[6] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
[J]. DIABETOLOGIA, 2004, 47 : A344 - A344
[7] COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION REGIMENS IN PATIENTS WITH TYPE 2 DIABETES IN SLOVAK SETTING
Psota, M.
Racekova, N.
Psenkova, M.
Vandebrouck, T.
Ramirez de Arellano, A.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
[8] A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Schmidt, I
Wittrup-Jensen, KW
[J]. DIABETES, 2004, 53 : A288 - A288
[9] Economic evaluation of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting
Tucker, DM
Wittrup-Jensen, KU
Roze, S
Valentine, WJ
Palmer, AJ
[J]. DIABETES, 2005, 54 : A609 - A609
[10] Economic evaluation of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type-1 diabetes in Germany
Palmer, AJ
Valentine, WJ
Wittrup-Jensen, KU
Roze, S
[J]. VALUE IN HEALTH, 2005, 8 (06) : A161 - A161

← 1 2 3 4 5 →